Payment overview · 2025
General Payments
$1,222.35
91 reported records · 17 companies
Healthcare provider profile · identity verified
Misty A Cundiff, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MONTICELLO, KY · NPI 1497178347
Verified facts
What the public records show
CMS Open Payments records show Misty A Cundiff, APRN received $1,222.35 in general payments during 2025 across 91 reported records.
Novo Nordisk Inc accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Farxiga, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Kerendia by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 259 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.81 | 16.7% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $202.72 | 16.6% | 20 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $194.26 | 15.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.21 | 11.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.87 | 11.4% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.65 | 4.1% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $45.15 | 3.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.94 | 3.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.16 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.01 | 3.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.17 | 2.5% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.43 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.77 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.58 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.84 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.25 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.53 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,222.35 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $202.72 | 20 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $194.26 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.15 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $138.15 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.44 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.65 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.90 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.90 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.97 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $50.65 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.95 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $45.15 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $44.94 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.17 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 124 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 259 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
121 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
124 | 24 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
259 | 35 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 659 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 503 | 54 |
| Gabapentin | Gabapentin | 457 | 56 |
| Omeprazole | Omeprazole | 448 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 64 |
| Lisinopril | Lisinopril | 322 | 68 |
| Ezetimibe | Ezetimibe | 291 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 50 |
| Furosemide | Furosemide | 268 | 50 |
| Mounjaro | Tirzepatide | 259 | 35 |
| Meloxicam | Meloxicam | 251 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 62 |
| Metformin Hcl | Metformin Hcl | 237 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 225 | 55 |
| Losartan Potassium | Losartan Potassium | 223 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 217 | 57 |
| Potassium Chloride | Potassium Chloride | 192 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 33 |
| Montelukast Sodium | Montelukast Sodium | 175 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 47 |
| Buspirone Hcl | Buspirone Hcl | 165 | 30 |
| Tramadol Hcl | Tramadol Hcl | 164 | 28 |
| Alprazolam | Alprazolam | 161 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 30 |
| Clonazepam | Clonazepam | 146 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 144 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 29 |
| Famotidine | Famotidine | 134 | 24 |
| Ozempic | Semaglutide | 134 | 22 |
| Ondansetron Odt | Ondansetron | 129 | 33 |
| Farxiga | Dapagliflozin Propanediol | 124 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 25 |
| Linzess | Linaclotide | 121 | 18 |
| Trazodone Hcl | Trazodone Hcl | 119 | 21 |
| Praluent Pen | Alirocumab | 115 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 23 |
| Sertraline Hcl | Sertraline Hcl | 107 | 18 |
| Carvedilol | Carvedilol | 104 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 103 | 68 |
| Eliquis | Apixaban | 97 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 16 |
| Meclizine Hcl | Meclizine Hcl | 89 | 18 |
| Jardiance | Empagliflozin | 87 | 20 |
| Methocarbamol | Methocarbamol | 87 | 22 |
| Pregabalin | Pregabalin | 87 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 84 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 59 |
| Clonidine Hcl | Clonidine Hcl | 79 | 11 |
| Allopurinol | Allopurinol | 78 | 12 |
| Fluconazole | Fluconazole | 76 | 38 |
| Rexulti | Brexpiprazole | 75 | suppressed |
| Simvastatin | Simvastatin | 75 | 13 |
| Prednisone | Prednisone | 74 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 69 | suppressed |
| Glipizide | Glipizide | 68 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 22 |
| Ibuprofen | Ibuprofen | 66 | 15 |
| Glipizide Er | Glipizide | 65 | 11 |
| Repatha Sureclick | Evolocumab | 62 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 15 |
| Januvia | Sitagliptin Phosphate | 58 | 14 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 12 |
| Spironolactone | Spironolactone | 58 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 57 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 56 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 13 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 52 | 13 |
| Azithromycin | Azithromycin | 51 | 40 |
| Diazepam | Diazepam | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 13 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Baclofen | Baclofen | 47 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 46 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 34 |
| Nabumetone | Nabumetone | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | 12 |
| Kerendia | Finerenone | 37 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Xifaxan | Rifaximin | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Roflumilast | Roflumilast | 29 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 20 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 12 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Tretinoin | Tretinoin | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,222.35 · 91 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FANAPT, FARXIGA, Kerendia, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TREMFYA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Wegovy, ZAVZPRET | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error